Destiny Pharma - DEST Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 31.25
+0 (0.00%)

This chart shows the closing price for DEST by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Destiny Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DEST and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DEST

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Destiny Pharma in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 31.25.

This chart shows the closing price for DEST for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Destiny Pharma. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/8/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/5/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/1/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/31/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/23/2022Shore CapitalReiterated RatingHouse Stock
7/27/2020FinnCapReiterated RatingCorporate
4/29/2020FinnCapReiterated RatingCorporate
3/3/2020FinnCapReiterated RatingCorporate
12/17/2019FinnCapReiterated RatingCorporate
10/16/2019FinnCapReiterated RatingCorporate
9/23/2019FinnCapReiterated RatingCorporate
9/10/2019FinnCapReiterated RatingCorporate
4/9/2019FinnCapReiterated RatingCorporate
1/25/2019FinnCapReiterated RatingCorporate
11/1/2018FinnCapReiterated RatingCorporate
9/26/2018FinnCapReiterated RatingCorporate
7/26/2018FinnCapReiterated RatingCorporate
7/17/2018FinnCapReiterated RatingCorporate
6/14/2018FinnCapReiterated RatingCorporate
5/24/2018FinnCapReiterated RatingCorporate
4/12/2018FinnCapReiterated RatingCorporateGBX 250
3/27/2018FinnCapInitiated CoverageCorporateGBX 250
(Data available from 12/1/2017 forward)

News Sentiment Rating

-0.02 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/5/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/4/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
7/4/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/3/2022
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/2/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
10/2/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/1/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/1/2022

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Destiny Pharma logo
Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase III clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in Phase I clinical trial for the treatment of skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Biofilm that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF drugs for the treatment of respiratory, oral mucosa, and ocular infection diseases. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; the University of Southampton; Aston University; the University of Sheffield; and Cardiff University and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.
Read More

Today's Range

Now: GBX 31.25
Low: 30.65
High: 31.85

50 Day Range

MA: GBX 35.17
Low: 31.25
High: 42.50

52 Week Range

Now: GBX 31.25
Low: 30.26
High: 118

Volume

84,514 shs

Average Volume

50,441 shs

Market Capitalization

£22.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Destiny Pharma?

The following Wall Street research analysts have issued stock ratings on Destiny Pharma in the last year: Shore Capital.
View the latest analyst ratings for DEST.

What is the current price target for Destiny Pharma?

0 Wall Street analysts have set twelve-month price targets for Destiny Pharma in the last year. has the lowest price target set, forecasting a price of £100,000 for Destiny Pharma in the next year.
View the latest price targets for DEST.

What is the current consensus analyst rating for Destiny Pharma?

Destiny Pharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for DEST.

What other companies compete with Destiny Pharma?

How do I contact Destiny Pharma's investor relations team?

Destiny Pharma's physical mailing address is Sussex Innovation Centre Science Park Square, Falmer, BRIGHTON, BN1 9SB, United Kingdom. The company's listed phone number is +44-1273-704440. The official website for Destiny Pharma is www.destinypharma.com. Learn More about contacing Destiny Pharma investor relations.